Volker Schellenberger | SVP Research Oncology
Vir Biotechnology, Inc.
Volker Schellenberger co-founded Amunix in 2006 and served as Chief Scientific Officer. He is the lead inventor of the company’s XTEN as well as XPAT platforms of protease-activated T cell engagers. Since the acquisition of Amunix by Sanofi in 2022, Volker directed discovery at Sanofi’s center of excellence for conditionally activated biologics. In 2024 the Amunix unit was licensed to Vir Biotechnology where Volker is SVP for Research Oncology leading the discovery of masked biologics. Volker has over 30 years of industry experience in protein engineering and drug discovery. Prior to co-founding Amunix he served as head of Genencor’s protein engineering department. Volker received his Ph.D. from Leipzig University (Germany) in 1986. He is author of over 40 scientific papers and inventor of more than 70 issued or pending patent applications. He is a recipient of the Karl Lohmann prize of the German Society of Biochemists.
Appearances:
Festival of Biologics Day 1 @ 16:50
XTEN Polypeptide-Masked Protease Activated T cell engagers: XPAT®[1] proteins - A novel format to mitigate the on-target, off-tumor problem
XPAT proteins are conditionally active T cell engagers (TCEs) designed to exploit the dysregulated protease activity in tumors. Preclinically, XPAT proteins demonstrated 1) Strong masking of in vitro cytotoxicity by approximately 4 logs; 2) Potent in vivo efficacy at doses similar to the efficacious doses of unmasked TCE controls; and 3) Increased MTDs in NHP by greater by >100 fold. Clinical trials of XPAT proteins targeting HER2 and PSMA are currently ongoing.
[1] XPAT® are registered Trademarks of Amunix Pharmaceuticals, Inc, a Sanofi company.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events